

benefit the workings of ACOT), and the nominee's field(s) of expertise; (2) a biographical sketch of the nominee and a copy of his/her curriculum vitae; and (3) the name, return address, and daytime telephone number at which the nominator can be contacted.

The Department of Health and Human Services has special interest in assuring that women, minority groups, and the physically disabled are adequately represented on advisory committees; and therefore, extends particular encouragement to nominations for appropriately qualified female, minority, or disabled candidates.

Dated: December 21, 2008.

**Elizabeth M. Duke,**

*Administrator, HRSA.*

[FR Doc. E8-31219 Filed 12-31-08; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **Proposed Collection; Comment Request; the Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research**

**SUMMARY:** In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget for review and approval.

**Proposed Collection: Title:** The impact of clinical research training and medical education at the Clinical Center on physician careers in academia and

clinical research: *Type of Information Collection Request:* New. *Need and Use of Information Collection:* This study will assess the value of the training programs administered by the Office of Clinical Research Training and Medical Education. The primary objective of the survey is to determine if training programs have had an impact on whether the trainees are performing clinical research, hold an academic appointment, have National Institutes of Health funding sources as well as to obtain information from the trainees as to what part of the National Institutes of Health medical education program they feel could be improved upon, the quality of the mentoring program, and how their National Institutes of Health training has contributed to their current clinical competence. *Frequency of response:* On occasion. *Affected Public:* Physicians, dentists, medical students, dental students, nurses, and PhDs. The annual reporting burden is as follows:

Type of respondents	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Doctoral Level .....	625	1	0.5	312.5
Students .....	100	1	0.5	50
Nurses .....	100	1	0.5	50
Total .....	.....	.....	.....	362.5

There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

**Request for Comments:** Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

**FOR FURTHER INFORMATION CONTACT:** To request more information on the proposed project or to obtain a copy of

the data collection plans and instruments, contact Linda Wisniewski, Nurse Consultant, Office of Clinical Research Training and Medical Education, CC, NIH, Building 10, Room 1N252B, 9000 Rockville Pike, Bethesda, MD 20892 or 301-496-9425 or e-mail your request, including your address to: [wisniewskil@cc.nih.gov](mailto:wisniewskil@cc.nih.gov).

**Comments Due Date:** Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: December 24, 2008.

**Laura Lee,**

*Project Clearance Liaison, Warren Grant Magnuson Clinical Center, National Institutes of Health.*

[FR Doc. E8-31240 Filed 12-31-08; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**ADDRESSES:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

### Novel Inhibitor of NF-kappa B Pathway

**Description of Technology:** Many tumors and blood cell cancers show overactivation of the NF-kappa B signal transduction pathway. This overactivation is associated with cancer forming in the colon, liver and other epithelial sites. In addition, there is evidence that overactivation leads to tumor formation and metastasis. However, this pathway is key for normal immunity, so any inhibition of NF-kappa B overactivation must avoid diminishing the body's ability to fight infection.

This invention claims a compound that inhibits NF-kappa B activation without affecting other transcription factors such as AP-1 and SRE binding proteins. It appears to function by blocking IKK beta and is effective at low micromolar concentrations without affecting cell proliferation or cell survival. At this low concentration, NF-kappa B is reduced to basal levels so this novel compound has prospects for preventing or treating cancer without being detrimental to immunity. In addition, because NF-kappa B overactivation contributes to a variety of inflammatory disorders including colitis, diabetes, prostatitis, and pancreatitis this compound has therapeutic applications beyond cancer.

#### Applications:

- Therapeutic for the chemoprevention or treatment of cancers associated with the overactivation of NF-kappa B signaling pathway.
- Therapeutic for the treatment of inflammatory disorders related to NF-kappa B overactivation.
- Reagent for the diagnosis of conditions related to overexpression of NF-kappa B.

#### Advantages:

- Highly specific inhibitor that allows targeting NF-kappa B without inhibiting other transcription factors.
- Effective at preventing carcinogenesis without affecting normal cell proliferation and survival.
- Therapeutic for treatment of cancer that will not compromise the immune system.

#### Development Status:

**Market:** Cancer is the second leading cause of death in the U.S. and it is estimated that 1.4 million Americans develop cancer in a year.

**Inventors:** Curtis J. Henrich *et al.* (NCI).

**Publications:** None related to invention have been published.

**Patent Status:** U.S. Provisional Application No. 61/098,977 filed 22 Sep 2008 (HHS Reference No. E-295-2008/0-US-01).

**Licensing Status:** Available for exclusive or non-exclusive licensing.

**Licensing Contact:** Sabarni K. Chatterjee, Ph.D.; 301-435-5587; [chatterjeesa@mail.nih.gov](mailto:chatterjeesa@mail.nih.gov).

**Collaborative Research Opportunity:** The National Cancer Institute (SAIC-Frederick) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize around development of analogs and/or further investigations of mechanism of action of the compound. Please contact John D. Hewes, Ph.D. at 301-435-3121 or [hewesj@mail.nih.gov](mailto:hewesj@mail.nih.gov) for more information.

### Method for Predicting and Detecting Tumor Metastasis

**Description of Technology:** Detecting cancer prior to metastasis greatly increases the efficacy of treatment and the chances of patient survival. Although numerous biomarkers have been reported to identify aggressive tumor types and predict prognosis, each biomarker is specific for a particular type of cancer, and no universal marker that can predict metastasis in a number of cancers have been identified. In addition, due to a lack of reliability, several markers are typically required to determine the prognosis and course of therapy.

The inventors discovered a novel CPE splice variant designated CPE-Δ N and found its expression levels increase according to the presence of cancer and metastasis wherein this variant is upregulated in tumors and further increased in metastatic cancer. This data has been demonstrated both in vitro and in vivo experiments and in liver, breast, prostate, colon, and head and neck cancers. Metastatic liver cells treated with CPE-Δ N siRNA reversed the cells from being metastatic and arrested cells from further metastasis. Thus, this novel CPE isoform is a biomarker for predicting metastasis and its inhibitors have an enormous potential to increase patient survival.

#### Applications:

- Method to prognose multiple types of cancer and determine likelihood of metastasis.
- Method to prevent and treat cancer with CPE inhibitors.
- Method to determine the stage of cancer development.

• CPE-Δ N pharmaceutical compositions.

**Development Status:** The technology is currently in the pre-clinical stage of development.

#### Market:

- Global cancer market is worth more than eight percent of total global pharmaceutical sales.
- Cancer industry is predicted to expand to \$85.3 billion by 2010.

**Inventors:** Y. Peng Loh *et al.* (NICHD).

**Patent Status:** U.S. Provisional Application No. 61/080,508 filed 14 Jul 2008 (HHS Reference No. E-234-2008/0-US-01).

**Licensing Status:** Available for exclusive or non-exclusive licensing.

**Licensing Contact:** Jennifer Wong; 301-435-4633; [wongje@mail.nih.gov](mailto:wongje@mail.nih.gov).

**Collaborative Research Opportunity:** The National Institute of Child Health and Human Development, Laboratory of Development Neurobiology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Method for Predicting and Detecting Tumor Metastasis. Please contact John D. Hewes, Ph.D. at 301-435-3121 or [hewesj@mail.nih.gov](mailto:hewesj@mail.nih.gov) for more information.

Dated: December 23, 2008.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E8-31238 Filed 12-31-08; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**ADDRESSES:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the